BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33376941)

  • 1. The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation.
    van den Dries CJ; van Doorn S; Souverein P; Pajouheshnia R; Moons KGM; Hoes AW; Geersing GJ; van den Ham HA
    TH Open; 2020 Oct; 4(4):e417-e426. PubMed ID: 33376941
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.
    Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ
    Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
    Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
    J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation.
    Douros A; Renoux C; Yin H; Filion KB; Suissa S; Azoulay L
    Am J Med; 2019 Feb; 132(2):191-199.e12. PubMed ID: 30691551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
    Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY;
    J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.
    Olsen AS; McGettigan P; Gerds TA; Fosbøl EL; Olesen JB; Sindet-Pedersen C; Staerk L; Lock Hansen M; Pallisgaard JL; Køber L; Torp-Pedersen C; Gislason GH; Lamberts M
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):292-300. PubMed ID: 31742339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-Analysis Assessing Efficacy and Safety of Vitamin K Antagonists Versus Direct Oral Anticoagulants for Atrial Fibrillation After Transcatheter Aortic Valve Implantation.
    Selvaraj V; Khan MS; Mufarrih SH; Kazimuddin M; Waheed MA; Tripathi A; Bavishi C; Hyder ON; Aronow HD; Saad M; Abbott JD
    Am J Cardiol; 2023 Aug; 201():260-267. PubMed ID: 37393728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.
    Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z
    Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
    Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
    Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
    Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
    Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions.
    Kirchmayer U; Narduzzi S; Mayer F; Tuccori M; Leoni O; Belleudi V; Di Martino M; Lallo A; Addis A; Davoli M
    Recenti Prog Med; 2019 Apr; 110(4):195-202. PubMed ID: 31066365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis.
    Zheng Y; Li S; Liu X; Lip GYH; Guo L; Zhu W
    Thromb Haemost; 2023 Jul; ():. PubMed ID: 37399842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants are associated with lower risk of dementia in patients with atrial fibrillation.
    Sagris D; Ntaios G; Buckley BJR; Harrison SL; Underhill P; Lane DA; Lip GYH
    Eur J Intern Med; 2024 Mar; 121():114-120. PubMed ID: 37914656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation.
    Harskamp RE; Teichert M; Lucassen WAM; van Weert HCPM; Lopes RD
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):615-623. PubMed ID: 31520256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation.
    Butt JH; De Backer O; Olesen JB; Gerds TA; Havers-Borgersen E; Gislason GH; Torp-Pedersen C; Søndergaard L; Køber L; Fosbøl EL
    Eur Heart J Cardiovasc Pharmacother; 2021 Jan; 7(1):11-19. PubMed ID: 31665260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study.
    Paschke LM; Klimke K; Altiner A; von Stillfried D; Schulz M
    BMC Med; 2020 Aug; 18(1):254. PubMed ID: 32847578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.